最近就0.75％丁吡卡因能否应用于产科麻醉引起争论,1983年8月美国食品及药品管理局建议不要用0.75％丁吡卡因于产科手术麻醉,因为有些报道说这样的浓度可引起心搏骤停。接着加拿大的有关部门要求加拿大生产丁吡卡因的厂商提醒医师和建议用于分娩时应减少药量。1983年8月Winthrop药厂写信给全加医师,提出0.75％丁吡卡因不得用于产科,对非孕妇的应用也要小心,该信还建议丁吡卡因不再用于产科宫颈旁阻滞,也不要用于区域性静脉麻醉。丁吡卡因心脏毒性问题,首先是由Albright医师提出,他在1979年报告了6例肯定是在血管内注射丁吡卡因或依替杜卡因后,立即发生心血管虚 The recent controversy over the possibility of applying pethidine for obstetric anesthetics at 0.75% was discontinued in August 1983 by the U.S. Food and Drug Administration for not obstetric surgery with 0.75% bupivacaine, as some reported that such concentrations can cause Cardiac arrest. Then Canadian authorities demanded that Canadian manufacturers of tetracinine remind physicians and advise doctors to reduce their doses when giving birth. August 1983 Winthrop Pharmaceuticals wrote to all-plus physicians that 0.75% tetracabromine should not be used for obstetric applications, but also for non-pregnant women should also be careful, the letter also suggested that tetracaine is no longer used for obstetric cervical Block, nor do you use regional venous anesthesia. The problem of toxopramic cardiotoxicity, first proposed by Albright’s physician, was reported in 1979 to 6 patients who were affirmative of immediate cardiovascular death after intravascular injection of bupivacaine or etidronate